Carcinogenesis Advance Access originally published online on August 12, 2004
Carcinogenesis 2004 25(12):2451-2458; doi:10.1093/carcin/bgh258
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.25 no.12 © Oxford University Press 2004; all rights reserved.
ARTICLE |
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers
1 Laboratory of Drug Metabolism, Division of Pharmacobio-dynamics, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan, 2 Division of Pharmacology and Therapeutics, Graduate School of Clinical Pharmacy, Kumamoto University, Kumamoto 862-0973, Japan, 3 Department of Medical Oncology, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan, 4 Maruyama Clinic, Sapporo 064-0820, Japan, 5 Biology Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan and 6 Department of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
7 To whom correspondence should be addressed Email: fujieda{at}pharm.hokudai.ac.jp
We reported previously that subjects homozygous for the cytochrome P450 2A6 (CYP2A6) *4 have a lower risk of lung cancer. The purpose of this study was to clarify whether or not the alterations of smoking behavior and risk for lung cancer could be found in subjects possessing novel CYP2A6 variants discovered recently. An epidemiological study was performed with 1094 cases and 611 controls in male Japanese smokers. It was found that the amounts of daily cigarette consumption in subjects who harbored CYP2A6*4/*7, *4/*10, *7/*7, *7/*9 and *4/*4 genotypes were significantly less than those in subjects carrying the *1/*1 genotype (P < 0.01). Even after adjustment with cigarette consumption, the adjusted odds ratios (ORs) for lung cancer were significantly lower in subjects who harbored CYP2A6*1/*4, *1/*7, *1/*9, *1/*10, *4/*4, *4/*7, *4/*9, *7/*7 and *7/*9 genotypes than those who possessed the *1/*1 genotype (P < 0.05). When participants were classified into four groups according to the CYP2A6 genotypes, group 1 (*1/*1), group 2 (heterozygotes for the *1 and a variant allele), group 3 (heterozygotes and homozygotes for variant alleles except for *4/*4) and group 4 (*4/*4), lung cancer risk was found to be less in subjects with the variant of CYP2A6 alleles {group 2, OR of 0.59 [95% confidence interval (CI), 0.44–0.79]; group 3, OR of 0.52 (95% CI, 0.37–0.72); group 4, OR of 0.30 (95% CI, 0.16–0.57)}. The reduced risk for lung cancer was seen more clearly in heavy smokers than in light smokers. Additional stratification analysis showed that the ORs for squamous cell carcinoma (OR of 0.07) and small cell carcinoma (OR of 0.10) were lower than that of adenocarcinoma (OR of 0.39) in group 4. These results suggest that the CYP2A6 is one of the principal determinants affecting not only smoking behavior but also susceptibility to tobacco-related lung cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Quaak, C. P. van Schayck, A. M. Knaapen, and F. J. van Schooten Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? Eur. Respir. J., March 1, 2009; 33(3): 468 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Rennard Lessons from Multidisciplinary Cross-Fertilization: Chronic Obstructive Pulmonary Disease, Lung Cancer, and Heart Disease Proceedings of the ATS, December 1, 2008; 5(8): 865 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gemignani, S. Landi, N. Szeszenia-Dabrowska, D. Zaridze, J. Lissowska, P. Rudnai, E. Fabianova, D. Mates, L. Foretova, V. Janout, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes Carcinogenesis, June 1, 2007; 28(6): 1287 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukami, M. Nakajima, H. Yamanaka, Y. Fukushima, H. L. Mcleod, and T. Yokoi A Novel Duplication Type of CYP2A6 Gene in African-American Population Drug Metab. Dispos., April 1, 2007; 35(4): 515 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kohno, T. Sakiyama, H. Kunitoh, K. Goto, Y. Nishiwaki, D. Saito, H. Hirose, T. Eguchi, N. Yanagitani, R. Saito, et al. Association of polymorphisms in the MTH1 gene with small cell lung carcinoma risk Carcinogenesis, December 1, 2006; 27(12): 2448 - 2454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Malaiyandi, S. D. Goodz, E. M. Sellers, and R. F. Tyndale CYP2A6 Genotype, Phenotype, and the Use of Nicotine Metabolites as Biomarkers during Ad libitum Smoking. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1812 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lee and R. F. Tyndale Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment J Psychopharmacol, July 1, 2006; 20(4_suppl): 7 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Casella, M. Miniati, S. Monti, F. Minichilli, F. Bianchi, and S. Simi No evidence of chromosome damage in chronic obstructive pulmonary disease (COPD) Mutagenesis, March 1, 2006; 21(2): 167 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kim, Z.-L. Wu, and F. P. Guengerich Analysis of Coumarin 7-Hydroxylation Activity of Cytochrome P450 2A6 using Random Mutagenesis J. Biol. Chem., December 2, 2005; 280(48): 40319 - 40327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Miyazaki, H. Yamazaki, H. Takeuchi, K. Saoo, M. Yokohira, K.-i. Masumura, T. Nohmi, Y. Funae, K. Imaida, and T. Kamataki Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas Carcinogenesis, November 1, 2005; 26(11): 1947 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kimura, H. Yamazaki, M. Fujieda, K. Kiyotani, G. Honda, J. Saruwatari, K. Nakagawa, T. Ishizaki, and T. Kamataki CYP2A6 IS A PRINCIPAL ENZYME INVOLVED IN HYDROXYLATION OF 1,7-DIMETHYLXANTHINE, A MAIN CAFFEINE METABOLITE, IN HUMANS Drug Metab. Dispos., September 1, 2005; 33(9): 1361 - 1366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fukami, M. Nakajima, E. Higashi, H. Yamanaka, H. Sakai, H. L. McLeod, and T. Yokoi CHARACTERIZATION OF NOVEL CYP2A6 POLYMORPHIC ALLELES (CYP2A6*18 AND CYP2A6*19) THAT AFFECT ENZYMATIC ACTIVITY Drug Metab. Dispos., August 1, 2005; 33(8): 1202 - 1210. [Abstract] [Full Text] [PDF]
|
|